Novo Nordisk (NYSE: NVO) is a Danish pharma heavyweight currently trading at undervalued levels, presenting an attractive ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Some of the losses are down to pharma's broader problems: notably, President Trump's tariff and price-cut threats. But there ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

Thermo Fisher Scientific has opened a 375,000-square-foot, carbon-neutral site in Mebane, N.C., designed to produce 40 ...

Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...